|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.58 INR | -2.99% |
|
-3.77% | -51.76% |
| 06-15 | Shukra Pharmaceuticals Limited Announces Management Changes, Effective June 15, 2026 | CI |
| 05-08 | Shukra Pharmaceuticals Swings to Consolidated Loss in Fiscal Q4 | MT |
| Market Cap | 13.29B 141M 123M 114M 106M 200M 204M 1.37B 528M 6.55B 528M 516M 22.76B | P/E 2024 |
19.3x | P/E 2025 | 99.9x |
|---|---|---|---|---|---|
| Enterprise Value | 13.21B 140M 122M 113M 105M 198M 203M 1.36B 525M 6.51B 525M 513M 22.62B | EV / Sales 2024 |
4.59x | EV / Sales 2025 | 29.1x |
| Free-Float |
11.03% | Yield 2024 |
1.22% | Yield 2025 | 0.05% |
| 1 week | -3.77% | ||
| Current month | -1.41% | ||
| 1 month | -1.41% | ||
| 3 months | -10.49% | ||
| 6 months | -53.67% | ||
| Current year | -51.76% |
| 1 week | 28.13 | 30.42 | |
| 1 month | 28.13 | 34.34 | |
| 3 years | 2.04 | 65.26 | |
| 5 years | 0.24 | 65.26 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 2012-05-25 | |
Anar Patel
DFI | Director of Finance/CFO | - | 2024-07-09 |
Shivkant Dhakad
CMP | Compliance Officer | - | 2026-06-14 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 45 | 2012-05-22 | |
| Chairman | 53 | - | |
| Director/Board Member | 51 | 2023-08-11 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.99% | -3.77% | +109.22% | +513.30% | 137M | ||
| +0.64% | +1.99% | +11.09% | +83.48% | 47.38B | ||
| +0.79% | +3.76% | +53.94% | +103.77% | 35.48B | ||
| +0.97% | +7.57% | -3.21% | +43.98% | 12.33B | ||
| +1.81% | +4.72% | +14.21% | +92.51% | 11.65B | ||
| -2.10% | +0.38% | +36.72% | +126.29% | 8.88B | ||
| -1.55% | +1.77% | +20.70% | +42.00% | 7.21B | ||
| +1.37% | +7.16% | +55.99% | -9.35% | 6.91B | ||
| +1.49% | -1.22% | +27.78% | +223.65% | 6.45B | ||
| +9.12% | +8.29% | -29.64% | +5.21% | 4.94B | ||
| Average | +1.39% | +3.53% | +29.68% | +122.49% | 15.69B | |
| Weighted average by Cap. | +0.89% | +3.14% | +24.58% | +85.98% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 765M 8.09M 7.08M 6.54M 6.1M 11.49M 11.75M 78.67M 30.37M 377M 30.37M 29.71M 1.31B | 326M 3.45M 3.02M 2.79M 2.6M 4.9M 5.01M 33.53M 12.94M 161M 12.94M 12.66M 558M |
| Net income | 185M 1.96M 1.72M 1.58M 1.48M 2.79M 2.85M 19.07M 7.36M 91.45M 7.36M 7.2M 318M | 95.75M 1.01M 887K 819K 764K 1.44M 1.47M 9.85M 3.8M 47.24M 3.8M 3.72M 164M |
| Net Debt | -68.26M -722K -632K -584K -545K -1.03M -1.05M -7.02M -2.71M -33.68M -2.71M -2.65M -117M | -79.41M -840K -735K -679K -634K -1.19M -1.22M -8.17M -3.15M -39.18M -3.15M -3.09M -136M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-29 | ₹28.58 | -2.99% | 112,404 |
| 26-06-25 | ₹29.46 | +0.44% | 208,706 |
| 26-06-24 | ₹29.33 | +0.45% | 111,369 |
| 26-06-23 | ₹29.20 | -1.68% | 123,500 |
| 26-06-22 | ₹29.70 | -1.82% | 230,823 |
- Stock Market
- Stocks
- 524632 Stock
- SHUKRAPHAR6 Stock
Select your edition
All financial news and data tailored to specific country editions
















